FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588894148> ?p ?o ?g. }

• W2588894148 abstract "Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Outcomes of interest were Event-Free Survival (EFS) up to 5 years after transplantation and mortality in the first 100 days after alloHCT. Outcomes were analyzed by means of the Kaplan-Meier method and Cox proportional hazards models with a frailty (random effects) component to take into account unexplained center heterogeneity. The following factors describing center characteristics or the transplant procedure were analyzed: experience in alloHCT in general and, for CLL specifically, accreditation by the Joint Accreditation Committee-ISCT & EBMT (JACIE), Gross National Income (GNI)/capita based on purchasing power parity (PPP) (GNI/cap), donor type, donor-patient sex-match, type of conditioning, stem cell source and T-cell depletion (TCD). Results:Five-year EFS of the whole cohort was 37% (95% Confidence Interval, 33%-42%), Day-100 survival was 90% (88%-92%). Experience of the transplant center was measured by the number of all alloHCTs, and alloHCTs for patients with CLL respectively. The median total number of alloHCTs per center per year was 45 (range 0-169) and the median number of CLL alloHCTs was only 2 per center per year (range 0-19). Greater experience with transplantation of patients with CLL (Hazard Ratio (HR) 0.96 per additional transplant, p=0.002), JACIE accreditation (HR 0.7, p=0.045) and a higher GNI/cap (HR 0.4, 95% CI 0.2-0.96, p=0.04) showed a protective impact on 5-year EFS in the Cox model. In vivo TCD with alemtuzumab (HR 1.5 compared to no TCD, p=0.03) and a female donor for a male patient (HR 1.4 compared to a male donor for a male patient, p=0.02) were the only procedure-related factors significantly associated with EFS. Event-Free Survival after in vivo TCD with Anti-Thymocyte-Globulin or after ex vivo TCD was comparable to EFS without TCD (HR 0.9, 0.7-1.3, p=0.6; HR 0.9, 0.5-1.6, p=0.8). Non-myeloablative conditioning did not have a negative impact on 5-year EFS, and exposed patients to a lower risk of non-relapse mortality. Measured and unmeasured center characteristics did not have a significant impact on 100-day mortality. Even when correcting for patient-, procedure- and center-related characteristics, there was still significant variation in center outcome, expressed by center-specific HRs derived from the frailty models, ranging from 0.6 to 1.2. Their impact is illustrated in a model-based plot for EFS (see Figure) which shows outcomes for three reference patients with the same characteristics who would be transplanted in three centers with the same measured characteristics but with the highest, average and lowest HRs in the dataset. These unexplained center effects likely represent a mixture of differences which could apply to the location of the transplant center, unmeasured characteristics of the patient population transplanted at this center, selection criteria which were not reported and factors determining the success of the transplant procedure which might differ between centers. Conclusion: We have confirmed that both center- and procedure-related factors have a significant impact on the EFS of patients with CLL undergoing alloHCT. Our results may help to interpret outcomes of single or multicenter studies better. Since non-myeloablative conditioning did not have a negative impact on EFS and exposed patients to a lower risk of non-relapse mortality, this approach should be favored for future alloHCT for CLL. Probability of Event-Free Survival up to Five Years Post-HCT for three Reference Patients Contribution: J.S. designed the research and wrote the paper. L.C.d.W conducted the statistical analysis and produced the figure. Figure Figure. Disclosures Schetelig: Sanofi: Honoraria. Gramatzki:Janssen: Other: Travel/Accommodation/Expenses, Research Funding. Dreger:Gilead: Consultancy; Gilead: Speakers Bureau; Janssen: Consultancy; Novartis: Speakers Bureau; Novartis: Consultancy; Roche: Consultancy." @default.
• W2588894148 created "2017-02-24" @default.
• W2588894148 creator A5001646221 @default.
• W2588894148 creator A5003531307 @default.
• W2588894148 creator A5004741011 @default.
• W2588894148 creator A5005303780 @default.
• W2588894148 creator A5006135894 @default.
• W2588894148 creator A5009079290 @default.
• W2588894148 creator A5011273153 @default.
• W2588894148 creator A5014405902 @default.
• W2588894148 creator A5020116063 @default.
• W2588894148 creator A5021274228 @default.
• W2588894148 creator A5024624218 @default.
• W2588894148 creator A5028262655 @default.
• W2588894148 creator A5036865975 @default.
• W2588894148 creator A5042854645 @default.
• W2588894148 creator A5056554686 @default.
• W2588894148 creator A5059011366 @default.
• W2588894148 creator A5059361091 @default.
• W2588894148 creator A5061020169 @default.
• W2588894148 creator A5070706427 @default.
• W2588894148 creator A5072027146 @default.
• W2588894148 creator A5073613763 @default.
• W2588894148 creator A5080330116 @default.
• W2588894148 creator A5083584684 @default.
• W2588894148 creator A5085132315 @default.
• W2588894148 creator A5085146093 @default.
• W2588894148 date "2016-12-02" @default.
• W2588894148 modified "2023-10-01" @default.
• W2588894148 title "Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT)" @default.
• W2588894148 doi "https://doi.org/10.1182/blood.v128.22.4663.4663" @default.
• W2588894148 hasPublicationYear "2016" @default.
• W2588894148 type Work @default.
• W2588894148 sameAs 2588894148 @default.
• W2588894148 citedByCount "0" @default.
• W2588894148 crossrefType "journal-article" @default.
• W2588894148 hasAuthorship W2588894148A5001646221 @default.
• W2588894148 hasAuthorship W2588894148A5003531307 @default.
• W2588894148 hasAuthorship W2588894148A5004741011 @default.
• W2588894148 hasAuthorship W2588894148A5005303780 @default.
• W2588894148 hasAuthorship W2588894148A5006135894 @default.
• W2588894148 hasAuthorship W2588894148A5009079290 @default.
• W2588894148 hasAuthorship W2588894148A5011273153 @default.
• W2588894148 hasAuthorship W2588894148A5014405902 @default.
• W2588894148 hasAuthorship W2588894148A5020116063 @default.
• W2588894148 hasAuthorship W2588894148A5021274228 @default.
• W2588894148 hasAuthorship W2588894148A5024624218 @default.
• W2588894148 hasAuthorship W2588894148A5028262655 @default.
• W2588894148 hasAuthorship W2588894148A5036865975 @default.
• W2588894148 hasAuthorship W2588894148A5042854645 @default.
• W2588894148 hasAuthorship W2588894148A5056554686 @default.
• W2588894148 hasAuthorship W2588894148A5059011366 @default.
• W2588894148 hasAuthorship W2588894148A5059361091 @default.
• W2588894148 hasAuthorship W2588894148A5061020169 @default.
• W2588894148 hasAuthorship W2588894148A5070706427 @default.
• W2588894148 hasAuthorship W2588894148A5072027146 @default.
• W2588894148 hasAuthorship W2588894148A5073613763 @default.
• W2588894148 hasAuthorship W2588894148A5080330116 @default.
• W2588894148 hasAuthorship W2588894148A5083584684 @default.
• W2588894148 hasAuthorship W2588894148A5085132315 @default.
• W2588894148 hasAuthorship W2588894148A5085146093 @default.
• W2588894148 hasConcept C126322002 @default.
• W2588894148 hasConcept C143998085 @default.
• W2588894148 hasConcept C2776694085 @default.
• W2588894148 hasConcept C2776755627 @default.
• W2588894148 hasConcept C2777408962 @default.
• W2588894148 hasConcept C2779263901 @default.
• W2588894148 hasConcept C2911091166 @default.
• W2588894148 hasConcept C71924100 @default.
• W2588894148 hasConcept C72563966 @default.
• W2588894148 hasConceptScore W2588894148C126322002 @default.
• W2588894148 hasConceptScore W2588894148C143998085 @default.
• W2588894148 hasConceptScore W2588894148C2776694085 @default.
• W2588894148 hasConceptScore W2588894148C2776755627 @default.
• W2588894148 hasConceptScore W2588894148C2777408962 @default.
• W2588894148 hasConceptScore W2588894148C2779263901 @default.
• W2588894148 hasConceptScore W2588894148C2911091166 @default.
• W2588894148 hasConceptScore W2588894148C71924100 @default.
• W2588894148 hasConceptScore W2588894148C72563966 @default.
• W2588894148 hasLocation W25888941481 @default.
• W2588894148 hasOpenAccess W2588894148 @default.
• W2588894148 hasPrimaryLocation W25888941481 @default.
• W2588894148 hasRelatedWork W2342022702 @default.
• W2588894148 hasRelatedWork W2433652219 @default.
• W2588894148 hasRelatedWork W2522316890 @default.
• W2588894148 hasRelatedWork W2551100722 @default.
• W2588894148 hasRelatedWork W2556222612 @default.
• W2588894148 hasRelatedWork W2559853404 @default.
• W2588894148 hasRelatedWork W2563132109 @default.
• W2588894148 hasRelatedWork W2577322383 @default.
• W2588894148 hasRelatedWork W2580088253 @default.
• W2588894148 hasRelatedWork W2589732589 @default.
• W2588894148 hasRelatedWork W2593766771 @default.
• W2588894148 hasRelatedWork W2594964815 @default.
• W2588894148 hasRelatedWork W2621348764 @default.
• W2588894148 hasRelatedWork W2749407443 @default.
• W2588894148 hasRelatedWork W2786688102 @default.
• W2588894148 hasRelatedWork W2979546703 @default.
• W2588894148 hasRelatedWork W2979622763 @default.
• W2588894148 hasRelatedWork W2988964011 @default.

• next